Gelonghui, May 17丨Yibai Pharmaceutical (600594.SH) announced that recently, the Guangdong Drug Trade Center issued the “Notice on Cancelling the Status of Guizhou Yibai Pharmaceutical Co., Ltd. Product Eddy Injection” to cancel the selection/alternative status of Guizhou Yibai Pharmaceutical Co., Ltd. product Eddy Injection in Guangdong according to the “Guangdong Alliance Qingkailing and Other Proprietary Chinese Medicines Centralized Volume Procurement Document (GDYJYPDL202103)” relating to “the suspension of production, sales, use, import, etc. of selected products by the drug administration department” The Alliance cleared the selected status for centralized procurement of proprietary Chinese medicines such as Kailing.

The company's product revenue for 2020, 2021, 2022 and 2023 was 737 million yuan, 693 million yuan, 480 million yuan, and 473 million yuan respectively, accounting for 21.61%, 20.71%, 17.57%, and 16.77% of the company's overall revenue; the revenue of Eddy Injection in the Guangdong Union supply area in 2020, 2021, 2022 and 2023 was 157 million yuan, 135 million yuan, 99 million yuan, and 108 million yuan respectively, accounting for Eddy Injections The operating income ratios were 21.31%, 19.53%, 20.51%, and 22.79%, respectively.

Eddy's injections are selected drugs from the Guangdong Alliance's centralized procurement of proprietary Chinese medicines such as Qingkailing. The delivery areas are Guangdong, Shanxi, Henan, Hainan, Ningxia, and Qinghai. Up to now, the supply agreements of the provinces in the above supply regions have not fully expired. After the company's product Eddy Injection was removed from the Guangdong Union's centralized procurement status for proprietary Chinese medicines such as Qingkailing, etc., Eddy's injection will not be able to continue to be supplied to the above regions until the supply agreements of the provinces within the above supply regions expire.